Men who drink two or more glasses of soda or other sweetened drinks a day may have a greater risk of heart failure, a Swedish study suggests. Previous research has linked high consumption of sugary beverages with several risk factors for heart failure, including high blood pressure, high blood sugar, weight gain, diabetes and obesity, […]

New York-based Bristol-Myers Squibb Company (BMY) announced today that it is acquiring Chapel Hill, N.C.-based Cardioxyl for up to about $2.07 billion.   Cardioxyl focuses on developing drugs for cardiovascular diseases. As part of the deal, Bristol-Myers Squib picks up the company’s lead asset, CXL-1427, a novel nitroxyl (HNO) donor (prodrug) that is currently in […]

Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study. The 448 patients in the trial were given an oral formulation of the drug omecamtiv mecarbil for 20 weeks and observed for 24 weeks, the companies […]

A biotech company founded by a Nobel prize winner has won the go-ahead from European regulators to begin the application process for conditional marketing authorization of a stem cell-based regenerative heart treatment. Conditional approval, if granted, would allow Cardiff-based Cell Therapy to start selling its Heartcel product for regenerating damaged areas of heart while continuing […]

Heart device maker St. Jude Medical Inc received a warning letter from the U.S. Food and Drug Administration, which said that various devices of the company manufactured at its Atlanta plant are adulterated. The health regulator in a letter dated Sept. 30 also warned that the company’s manufacturing, packing, storage and installation practices “are not […]

Novartis AG’s new heart failure drug Entresto is on track to be approved for use in Europe by the end of the year after it received the backing of EU regulators, the company said on Friday.   Entresto, also known as LCZ696, is the first new drug in decades for helping patients whose lives are […]

Eli Lilly and Co’s new Jardiance pill slashed deaths by 32 percent in a study of 7,000 patients with type 2 diabetes at risk of heart attack and stroke, a finding that researchers said could make it a mainstay diabetes treatment. “This is the first diabetes therapy to show robust effect in reducing cardiovascular death. […]

Novartis AG’s (NVS -1.46 %) new heart-failure treatment should cost about 17% less than what the company is charging in the U.S. because wide use of the drug would strain health-care budgets, a nonprofit research group said Friday. Entresto’s U.S. list price, also known as its wholesale acquisition cost, is $12.50 a day, or about […]

A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER. In a draft report released on Friday, the Boston-based Institute for Clinical and Economic Review […]

Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial. Having done well with recently launched drugs like stroke prevention pill Xarelto and eye treatment Eylea, the German group is eager to […]